Profile
Michael W.
Stevenson worked as Senior Director-Medical Affairs at FORUM Pharmaceuticals, Inc. from 2013 to 2015.
Prior to that, he was Executive Director-Medical Affairs at AMAG Pharmaceuticals, Inc. from 2008 to 2012.
He also worked as Vice President-Medical Affairs at Akcea Therapeutics, Inc. Dr. Stevenson received his undergraduate degree from Duquesne University of The Holy Spirit and his doctorate degree from Louisiana State University.
Former positions of Michael W. Stevenson
Companies | Position | End |
---|---|---|
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | 2015-09-30 |
AMAG PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2012-10-31 |
AKCEA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Training of Michael W. Stevenson
Duquesne University of The Holy Spirit | Undergraduate Degree |
Louisiana State University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Health Technology |
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- Michael W. Stevenson